glp 1 and colon cancer Emerging Evidence Positions GLP-1 Receptor Agonists as a Novel Strategy to Reduce CRC Risk GLP-1 Weight-Loss Meds Linked to

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement

In particular, sexual dysfunction (i.e., reduced libido, reduced spontaneous or stimulated penile erection, and erectile dysfunction), hot flashes, reduced semen volume, and decreased hair in androgen-dependent areas are the main signs and symptoms detectable [Figure 1]

examined how chronic hepatitis B virus (HBV)- related gut microbiota imbalance affects miR-1925p and GLP-1 expression in 2018

Nearly half of surveyed payers plan to differentiate the PA process for GLP-1s based on indication, by excluding coverage for obesity and allowing restricted coverage for comorbidities